ticker: VRTX
step: 01
generated: 2026-05-12
source: quick-research
Vertex Pharmaceuticals Inc. (VRTX) — Business Overview
Business Description
Vertex Pharmaceuticals is a global biotech with a near-monopoly franchise in cystic fibrosis (CF) treatment (Trikafta, Symdeko, Kalydeco, and the newer ALYFTREK). After 25 years of single-disease focus, Vertex is mid-execution on a major diversification: CASGEVY (CRISPR gene therapy for sickle cell + beta thalassemia, partnered with CRISPR Therapeutics), JOURNAVX (first-in-class non-opioid NaV1.8 acute pain inhibitor launched March 2025), zimislecel (potentially curative T1 diabetes cell therapy), and povetacicept (autoimmune kidney disease). CEO Reshma Kewalramani has led the diversification since 2020.
Revenue Model
- Cystic Fibrosis (~80% of revenue): Trikafta, ALYFTREK (newer triple combo), Symdeko, Kalydeco
- Non-CF launches (~5%, growing): CASGEVY (gene therapy), JOURNAVX (acute pain) — targeting $500M+ in 2026
- Royalties + other (~15%): CRISPR Therapeutics royalties + minor revenue streams
Products & Services
Cystic Fibrosis (Core franchise, near-monopoly)
- Trikafta (Kaftrio in EU): Triple combo — ~90% of CF patients eligible; $2.35B Q1 2026 (-7%)
- ALYFTREK (vanzacaftor + 2 others): Newest CFTR modulator, surpassed $1B cumulative; FDA approved Dec 2024
- Symdeko, Kalydeco, Orkambi: Older CFTR modulators (declining)
- CTX-Sigma: Next-gen CF for difficult-to-treat mutations (clinical)
Beyond CF (Diversification — $500M+ 2026 target)
- CASGEVY: CRISPR/Cas9 gene therapy for sickle cell disease (SCD) + transfusion-dependent beta thalassemia (TDT)
- Approved Dec 2023 (US) and Q1 2024 (EU); first CRISPR-edited therapy
- 500+ patients initiated treatment; 64 infusions in 2025
- Partnership with CRISPR Therapeutics (50/50)
- JOURNAVX (suzetrigine, VX-548):
- First-in-class NaV1.8 oral non-opioid for moderate-severe acute pain
- Approved March 2025; 1M+ Rx filled to date
- 150 additional sales reps added Q1 2026
- Neuropathic pain Phase 3 ongoing
- Zimislecel: Stem cell-derived islet replacement for Type 1 diabetes
- Phase 1/2 dosing complete H1 2026
- Phase 3 enrolled (dosing temporarily postponed)
- Povetacicept (Pavle Tx): Anti-APRIL antibody for autoimmune kidney disease (IgAN, lupus)
- VX-770/Inaxaplin: APOL1-mediated kidney disease
Customer Base & Go-to-Market
- CF patients: ~85K eligible globally; Vertex has near-100% share
- Sickle cell + TDT patients: CASGEVY administered at Authorized Treatment Centers (ATCs)
- Acute pain patients: Post-surgical, dental, ER patients prescribing JOURNAVX
- T1D patients: Future zimislecel addressable market large
- Geographic mix: ~70% US, ~30% International
- Channel: Specialty pharmacy for CF; ATC network for CASGEVY; retail + hospital for JOURNAVX
Competitive Position
Vertex has the closest thing to a monopoly in biotech: near-100% share of CF treatment globally. Moats: (1) decades of CFTR mutation chemistry expertise, (2) CRISPR/Cas9 partnership with CRISPR Therapeutics, (3) first-in-class NaV1.8 mechanism for non-opioid pain, (4) substantial cash + free cash flow to fund diversification. Faces (1) AbbVie/Galapagos entering CF (small risk), (2) generic competitors as Kalydeco loses exclusivity, (3) emerging gene therapy competition from BluebirdBio (Lyfgenia for SCD).
Key Facts
- Founded: 1989 (Joshua Boger)
- Headquarters: Boston, MA
- Employees: ~5,500
- Exchange: NASDAQ
- Sector / Industry: Health Care / Biotechnology
- Market Cap: ~$110B (May 2026)
- CEO: Dr. Reshma Kewalramani (since April 2020)
- No dividend
- FY end: December